Application of two-dimensional transition metal sulfide in preparation of medicine for treating and / or preventing pneumonia

By using two-dimensional transition metal sulfide nanomaterials to inhibit inflammatory factors in pneumonia cells, the problem of difficulty in treating pneumonia in the prior art is solved, and effective treatment and prevention of pneumonia is achieved without toxic effects.

CN118948885AInactive Publication Date: 2024-11-15HEBEI AGRICULTURAL UNIV.
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411323201.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult in the treatment and prevention of pneumonia. The excessive use of antibiotics and antiviral drugs has led to an increase in the rate of bacterial and viral resistance, and the lack of novel safe and effective therapeutic drugs.

Method used

Two-dimensional transition metal sulfides, such as tungsten disulfide, tungsten diselenide, niobium disulfide, niobium diselenide, niobium diselenide, are used as nanomaterials to prepare drugs for treatment and prevention of pneumonia by inhibiting the inflammatory factor TNF in pneumonia cells Alpha and IL-6 levels increased.

Benefits of technology

Two-dimensional transition metal sulfide significantly reduced the levels of TNF-α and IL-6 inflammatory factors in pneumonia cells and mice, and did not have a significant toxic effect on mice, providing new drug ideas for the treatment and prevention of pneumonia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948885A_ABST
    Figure CN118948885A_ABST
Patent Text Reader

Abstract

The invention provides application of a two-dimensional transition metal sulfide in preparation of a medicine for treating and / or preventing pneumonia, and belongs to the technical field of medicines. The tungsten disulfide, the tungsten diselenide, the niobium disulfide and the niobium diselenide can remarkably reduce the level of TNF-alpha and IL-6 inflammatory factors in MH-S cells and serum of pneumonia mice, and do not generate a remarkable toxic effect on the mice, so that the two-dimensional transition metal sulfide can be used for preparing the medicine for treating and / or preventing pneumonia; a new thought is provided for the treatment of pneumonia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to the use of two-dimensional transition metal sulfides in preparing drugs for treating and / or preventing pneumonia. Background Art

[0002] Two-dimensional transition metal dichalcogenides (2D TMDs) are MX2-type compounds composed of transition metal atoms (M) and chalcogen atoms (X). 2D TMDs have a layered structure similar to graphene. The metal atoms in the layer are covalently bonded to the chalcogen non-metal atoms. There are weak van der Waals forces between the layers. Therefore, destroying the weak forces between the layers can prepare 2D TMDs nanosheets. 2D TMDs have special physical and chemical properties and have been widely used in transistors, lithium-ion batteries, gas sensors, integrated circuits, and photodetectors. At the same time, 2D TMDs show good development potential in biomedical fields such as biosensing, imaging, and tumor therapy. However, the intrinsic biological activity of two-dimensional transition metal dichalcogenides in biomedical applications has long been ignored.

[0003] Pneumonia refers to inflammation of the terminal airways, alveoli and lung interstitium, which can generally be caused by pathogenic microorganisms such as bacteria, viruses, fungi, parasites, as well as physical and chemical factors such as radiation or inhaled foreign bodies. The main clinical manifestations are fever, chills, cough, sputum, blood in sputum, and a few patients will experience symptoms such as dyspnea. Bacterial pneumonia is often treated with antibiotics, while viral pneumonia is ineffective with antibiotics and requires the use of antiviral drugs. In recent years, the extensive use of antibiotics and antiviral drugs has led to an increase in the resistance rate of bacteria and viruses, which often leads to treatment failure. Therefore, it is urgent to find new, safe and effective therapeutic drugs. Summary of the invention

[0004] The purpose of the present invention is to provide the use of two-dimensional transition metal sulfides in the preparation of drugs for treating and / or preventing pneumonia, thereby solving the problem of difficulty in treating pneumonia in the prior art.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides the use of two-dimensional transition metal sulfide in preparing medicine for treating and / or preventing pneumonia.

[0007] Preferably, the two-dimensional transition metal sulfide includes tungsten disulfide, tungsten diselenide, niobium disulfide, and niobium diselenide.

[0008] Preferably, the two-dimensional transition metal sulfide is a two-dimensional nanomaterial.

[0009] Preferably, the thickness of the two-dimensional transition metal sulfide is 4 to 5 nm, and the size of the two-dimensional transition metal sulfide is 200 to 400 nm.

[0010] The present invention also provides the use of two-dimensional transition metal sulfide in preparing a drug for inhibiting the increase of inflammatory factor levels in a pneumonia body.

[0011] Preferably, the inflammatory factors include TNF-α and IL-6.

[0012] Preferably, the medicine for treating and / or preventing pneumonia comprises an injection.

[0013] Preferably, the injection dose of the two-dimensional transition metal sulfide is 1 to 3 mg / kg.

[0014] The present invention also provides the use of two-dimensional transition metal sulfide in preparing a drug for inhibiting the increase of inflammatory factor levels in pneumonia cells; the inflammatory factors include TNF-α and IL-6.

[0015] Preferably, the concentration of the two-dimensional transition metal sulfide in the cell culture medium is 10 to 25 cm 2 / mL.

[0016] By adopting the above technical scheme, the present invention has the following beneficial effects: the tungsten disulfide, tungsten diselenide, niobium disulfide and niobium diselenide of the present invention can significantly reduce the levels of TNF-α and IL-6 inflammatory factors in pneumonia cells and pneumonia mice, and do not produce significant toxic effects on mice, indicating that two-dimensional transition metal sulfides can be used to prepare drugs for treating and / or preventing pneumonia, providing a new idea for the treatment of pneumonia. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a graph showing the secretion level of TNF-α in alveolar macrophages of mice in different groups in Example 1.

[0018] Figure 2 This is a graph showing the secretion levels of IL-6 in alveolar macrophages of mice in different groups in Example 1.

[0019] Figure 3 This is a graph showing the concentration levels of TNF-α and IL-6 in the bronchoalveolar lavage fluid of C57BL / 6J mice in different groups in Example 2.

[0020] Figure 4 This is a graph showing the body weight of C57BL / 6J mice in different groups in Example 3.

[0021] Figure 5 This is a graph showing the concentrations of alanine aminotransferase (ALT), total protein (TP), serum albumin (ALB), and urea nitrogen (UREA) in different groups of C57BL / 6J mice in Example 3. DETAILED DESCRIPTION

[0022] The present invention provides the use of a two-dimensional transition metal sulfide in the preparation of a drug for treating and / or preventing pneumonia, wherein the two-dimensional transition metal sulfide includes tungsten disulfide, tungsten diselenide, niobium disulfide, and niobium diselenide; the two-dimensional transition metal sulfide is a two-dimensional nanomaterial. The thickness of the two-dimensional transition metal sulfide is 4 to 5 nm, more preferably 4.2 to 4.8 nm, and more preferably 4.5 nm; the size of the two-dimensional transition metal sulfide is 200 to 400 nm, more preferably 250 to 350 nm, and more preferably 300 nm.

[0023] The present invention also provides the use of two-dimensional transition metal sulfides in the preparation of drugs for inhibiting the increase of inflammatory factor levels in pneumonia bodies, wherein the inflammatory factors include TNF-α and IL-6; the drug for treating and / or preventing pneumonia includes an injection, and the injection dose of the two-dimensional transition metal sulfide is 1 to 3 mg / kg, more preferably 1.5 to 2.5 mg / kg, and more preferably 2 mg / kg.

[0024] The present invention also provides the use of two-dimensional transition metal sulfide in the preparation of a drug for inhibiting the increase of inflammatory factor levels in pneumonia cells; the inflammatory factors include TNF-α and IL-6; the concentration of the two-dimensional transition metal sulfide in the cell culture medium is 10 to 25 cm 2 / mL, more preferably 15 to 20 cm 2 / mL, more preferably 18cm 2 / mL.

[0025] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0026] The tungsten disulfide, tungsten diselenide, niobium disulfide and niobium diselenide nanomaterials of the embodiments of the present invention were purchased from Jiangsu Xianfeng Nanomaterial Technology Co., Ltd.

[0027] MH-S cells were purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences;

[0028] ELISA kits were purchased from Invitrogen Life Technologies, USA, with catalog numbers: IL-6: 254425-005, TNF-α: 234277-013;

[0029] C57BL / 6J mice (5 weeks old) were purchased from the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College. All animal experiments were approved by the Animal Care and Use Committee of Hebei Agricultural University and were performed in accordance with the guidelines of the National Institutes of Health (NIH) in the “Guide for the Care and Use of Laboratory Animals”.

[0030] Example 1 Cell experiment

[0031] The experiment was divided into a blank group, a model group, a tungsten disulfide group, a tungsten diselenide group, a niobium disulfide group, and a niobium diselenide group. MH-S cells in the logarithmic growth phase were taken and 1×10 4 The cells were seeded at a density of 100 / well on a 96-well plate. The model group, tungsten disulfide, tungsten diselenide, niobium disulfide, and niobium diselenide groups were treated with lipopolysaccharide (LPS) at a concentration of 20 ng / mL for 24 h to stimulate MH-S cells to establish a pneumonia cell model. Then, each group of tungsten disulfide, tungsten diselenide, niobium disulfide, and niobium diselenide was divided into 4 groups. The tungsten disulfide group was used as an example for explanation: the tungsten disulfide group was further divided into tungsten disulfide-1, tungsten disulfide-2, tungsten disulfide-3, and tungsten disulfide-4. Among them, tungsten disulfide-1 group was added with a concentration of 10 cm 2 / mL of tungsten disulfide was added to continue incubation, and tungsten disulfide-2 group was added at a concentration of 10cm 2 / mL of tungsten disulfide and 3MA, an autophagy inhibitor at a concentration of 5mM, were co-incubated. Tungsten disulfide-3 group was added at a concentration of 25cm 2 / mL of tungsten disulfide was added to continue incubation, and tungsten disulfide-4 group was added at a concentration of 25cm 2 / mL of tungsten disulfide and 5mM of autophagy inhibitor 3MA were co-incubated. The treatment of the small groups in each group of tungsten diselenide, niobium disulfide, and niobium diselenide was referred to the tungsten disulfide group, and the blank group was not treated. After continuing to culture in a 37°C cell culture incubator for 24 hours, the cell supernatant of each group was collected, and the concentrations of TNF-α and IL-6 in the supernatant were determined by ELISA kits. The results are shown in Figure 1 and Figure 2 As shown. Figure 1 and Figure 2 It can be seen that tungsten disulfide, tungsten diselenide, niobium disulfide, and niobium diselenide are at 10 and 25 cm 2 / mL significantly alleviated the inflammatory response of mouse alveolar macrophages induced by lipopolysaccharide (LPS). In addition, the addition of the autophagy inhibitor 3MA reversed the alleviation of the inflammatory response caused by tungsten disulfide, tungsten diselenide, niobium disulfide, and niobium diselenide.

[0032] Example 2 Animal Experiment

[0033] Five-week-old C57BL / 6J mice were taken and adaptively fed for one week. The mice were divided into 6 groups, namely control group, model group (LPS), tungsten disulfide group, tungsten diselenide group, niobium disulfide group, and niobium diselenide group, with 3 mice in each group. Lipopolysaccharide LPS was intraperitoneally injected into mice at a dose of 20 mg / kg to establish an acute lung injury (ALI) model in mice. The modeling was completed after 40 hours, and the control group was not treated. Significant inflammatory cell infiltration was found in the pathological sections of the lung tissue of the modeled mice, indicating that the modeling was successful. 40 hours after the administration of lipopolysaccharide LPS, tungsten disulfide, tungsten diselenide, niobium disulfide, and niobium diselenide were intravenously injected at a dose of 2 mg / kg, and the mice in the control group were injected with an equal amount of normal saline. Then, 24 hours after treatment with tungsten disulfide, tungsten diselenide, niobium disulfide, and niobium diselenide, the mice were killed, and a hole was made in the mouse main trachea near the head with a syringe needle. A 1mL syringe with a flat needle was inserted into the trachea, and the needle inserted into the trachea was ligated and fixed with surgical sutures. 0.5mL of lavage fluid was drawn into the mouse lungs with a syringe and gently pushed into the mouse lungs. The mouse chest was gently touched with the thumb several times, and the lavage fluid was slowly withdrawn. This operation was repeated 3 times. The collected alveolar lavage fluid was centrifuged (4°C, 1500rpm×15min), the supernatant was taken, and stored at -80°C. For the collected mouse alveolar lavage fluid supernatant, the inflammatory factors TNF-α and IL-6 in the mouse alveolar lavage fluid were measured according to the instructions of the ELISA detection kit. The results are as follows. Figure 3 shown. Figure 3 The results showed that lipopolysaccharide (LPS) treatment significantly increased the levels of inflammatory factors TNF-α and IL-6, while further exposure to tungsten disulfide, tungsten diselenide, niobium disulfide, and niobium diselenide significantly inhibited the increase in TNF-α and IL-6 levels caused by lipopolysaccharide (LPS).

[0034] Example 3 Toxicity Experiment

[0035] Five-week-old C57BL / 6J mice were taken and adaptively fed for one week. Then the mice were divided into 6 groups, namely control group, model group (LPS), tungsten disulfide group, tungsten diselenide group, niobium disulfide group, and niobium diselenide group, with 3 mice in each group. Lipopolysaccharide LPS was intraperitoneally injected into mice at a dose of 20 mg / kg to establish an acute lung injury (ALI) model in mice. The modeling was completed after 40 hours, and the control group was not treated. Significant inflammatory cell infiltration was found in the pathological sections of the lung tissue of the modeled mice, indicating that the modeling was successful. 40 hours after the administration of lipopolysaccharide LPS, tungsten disulfide, tungsten diselenide, niobium disulfide, and niobium diselenide were intravenously injected at a dose of 2 mg / kg, respectively. The mice in the control group were injected with an equal amount of normal saline. The weight of the mice was weighed and recorded before each drug addition. The weight changes of the mice are as follows Figure 4Then, 24 hours after the treatment with tungsten disulfide, tungsten diselenide, niobium disulfide, and niobium diselenide, the mice were killed and the serum was collected. The concentrations of alanine aminotransferase (ALT), total protein (TP), serum albumin (ALB), and urea nitrogen (UREA) in the serum of each group of mice were detected using an automatic serum biochemical analyzer (model: Chemray 240). The results are shown in Figure 5 shown.

[0036] Depend on Figure 4 and Figure 5 It can be seen that treatment with tungsten disulfide, tungsten diselenide, niobium disulfide and niobium diselenide will not have a significant effect on the body weight of mice and biochemical indicators such as alanine aminotransferase (ALT), total protein (TP), serum albumin (ALB), and urea nitrogen (UREA) in the mouse serum, indicating that exposure to lipopolysaccharide LPS, tungsten disulfide, tungsten diselenide, niobium disulfide and niobium diselenide did not produce significant toxic effects on C57BL / 6J mice.

[0037] It can be seen from the above embodiments that the present invention provides the use of two-dimensional transition metal sulfides in the preparation of drugs for treating and / or preventing pneumonia, which provides a new idea for the treatment of pneumonia.

[0038] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of two-dimensional transition metal sulfides in the preparation of drugs for treating and / or preventing pneumonia.

2. The use according to claim 1, characterized in that: The two-dimensional transition metal sulfide includes tungsten disulfide, tungsten diselenide, niobium disulfide and niobium diselenide.

3. The use according to claim 2, characterized in that: The two-dimensional transition metal sulfide is a two-dimensional nanomaterial.

4. The use according to claim 3, characterized in that: The thickness of the two-dimensional transition metal sulfide is 4 to 5 nm, and the size of the two-dimensional transition metal sulfide is 200 to 400 nm.

5. Application of two-dimensional transition metal sulfides in the preparation of drugs for inhibiting the increased levels of inflammatory factors in pneumonia.

6. The use according to claim 5, characterized in that: The inflammatory factors include TNF-α and IL-6.

7. The use according to any one of claims 1 to 6, characterized in that: The medicine for treating and / or preventing pneumonia includes injection.

8. The use according to claim 7, characterized in that: The injection dosage of the two-dimensional transition metal sulfide is 1 to 3 mg / kg.

9. Use of two-dimensional transition metal sulfides in the preparation of drugs for inhibiting the increase in the level of inflammatory factors in pneumonia cells; the inflammatory factors include TNF-α and IL-6.

10. The use according to claim 9, characterized in that: The concentration of the two-dimensional transition metal sulfide in the cell culture medium is 10 to 25 cm 2 / mL.

Citation Information

Patent Citations

  • Pharmaceutical composition containing TMD nanosheets as active ingredient and used for treating burns

    CN117651558A

  • Biopolymer-coated two-dimensional transition metal chalcogenides having potent antimicrobial activity

    US20210289791A1

  • Use of two-dimensional nanomaterial in inhibition of coronavirus

    US20240091167A1